What do systematic reviews say?

Paracetamol (single administration, any dose) vs placebo

Paracetamol (single administration, any dose) showed no clear difference in maternal drug adverse effects (sleepiness) compared with placebo (low certainty).

• Paracetamol/acetaminophen (single administration) for perineal pain in the early postpartum period 2021 · Cochrane Headline outcomes only
  RR 0.89 [0.18, 4.3]
  1 study · 232 participants
  Low

Paracetamol (single administration, any dose) vs placebo

The review found no eligible studies for this question.

• Paracetamol/acetaminophen (single administration) for perineal pain in the early postpartum period 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Recombinant human thyrotropin‐aided radioiodine vs radioiodine

• Recombinant human thyrotropin (rhTSH)‐aided radioiodine treatment for non‐toxic multinodular goitre 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 85 participants
  Very low

Recombinant human thyrotropin‐aided radioiodine vs radioiodine

Recombinant human thyrotropin‐aided radioiodine probably leads to higher hypothyroidism compared with radioiodine (moderate certainty).

• Recombinant human thyrotropin (rhTSH)‐aided radioiodine treatment for non‐toxic multinodular goitre 2021 · Cochrane Headline outcomes only
  RR 2.53 [1.52, 4.2]
  6 studies · 321 participants
  Moderate

Recombinant human thyrotropin‐aided radioiodine vs radioiodine

Recombinant human thyrotropin‐aided radioiodine showed no clear difference in adverse events compared with radioiodine (low certainty).

• Recombinant human thyrotropin (rhTSH)‐aided radioiodine treatment for non‐toxic multinodular goitre 2021 · Cochrane Headline outcomes only
  RR 1.24 [0.94, 1.63]
  6 studies · 321 participants
  Low

Recombinant human thyrotropin‐aided radioiodine vs radioiodine

• Recombinant human thyrotropin (rhTSH)‐aided radioiodine treatment for non‐toxic multinodular goitre 2021 · Cochrane Headline outcomes only
  no estimate extracted
  6 studies · 268 participants
  Moderate

Recombinant human thyrotropin‐aided radioiodine vs radioiodine

• Recombinant human thyrotropin (rhTSH)‐aided radioiodine treatment for non‐toxic multinodular goitre 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 28 participants
  Very low

Recombinant human thyrotropin‐aided radioiodine vs radioiodine

The review found no eligible studies for this question.

• Recombinant human thyrotropin (rhTSH)‐aided radioiodine treatment for non‐toxic multinodular goitre 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

• Abdominal ultrasound and alpha‐foetoprotein for the diagnosis of hepatocellular carcinoma in adults with chronic liver… 2021 · Cochrane Headline outcomes only
  no estimate extracted
  147 studies · 52144 participants
  Very low

Intervention not reported

• Abdominal ultrasound and alpha‐foetoprotein for the diagnosis of hepatocellular carcinoma in adults with chronic liver… 2021 · Cochrane Headline outcomes only
  no estimate extracted
  56 studies · 20452 participants
  Very low

Intervention not reported

• Abdominal ultrasound and alpha‐foetoprotein for the diagnosis of hepatocellular carcinoma in adults with chronic liver… 2021 · Cochrane Headline outcomes only
  no estimate extracted
  39 studies · 18792 participants
  Very low

Intervention not reported

• Abdominal ultrasound and alpha‐foetoprotein for the diagnosis of hepatocellular carcinoma in adults with chronic liver… 2021 · Cochrane Headline outcomes only
  no estimate extracted
  6 studies · 5044 participants
  Low

Intervention not reported

• Abdominal ultrasound and alpha‐foetoprotein for the diagnosis of hepatocellular carcinoma in adults with chronic liver… 2021 · Cochrane Headline outcomes only
  no estimate extracted
  6 studies · 5044 participants
  Low

Intervention not reported

• Abdominal ultrasound and alpha‐foetoprotein for the diagnosis of hepatocellular carcinoma in adults with chronic liver… 2021 · Cochrane Headline outcomes only
  no estimate extracted
  6 studies · 5044 participants
  Low

Intervention not reported

• Computed tomography for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease 2021 · Cochrane Headline outcomes only
  no estimate extracted
  21 studies · 3101 participants
  Low

Intervention not reported

• Computed tomography for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease 2021 · Cochrane Headline outcomes only
  no estimate extracted
  10 studies · 1854 participants
  Low

Effect of LF‐LAM vs no LF‐LAM on mortality and tuberculosis treatment initiation

Effect of LF‐LAM probably leads to lower mortality at 8 weeks compared with no LF‐LAM on mortality and tuberculosis treatment initiation (moderate certainty).

• Impact of diagnostic strategies for tuberculosis using lateral flow urine lipoarabinomannan assay in people living… 2021 · Cochrane Headline outcomes only
  RR 0.85 [0.76, 0.94]
  2 studies · 5102 participants
  Moderate

Effect of LF‐LAM vs no LF‐LAM on mortality and tuberculosis treatment initiation

Effect of LF‐LAM showed no clear difference in people started on tuberculosis treatment compared with no LF‐LAM on mortality and tuberculosis treatment initiation (moderate certainty).

• Impact of diagnostic strategies for tuberculosis using lateral flow urine lipoarabinomannan assay in people living… 2021 · Cochrane Headline outcomes only
  RR 1.26 [0.94, 1.69]
  2 studies · 5102 participants
  Moderate
• Impact of diagnostic strategies for tuberculosis using lateral flow urine lipoarabinomannan assay in people living… 2021 · Cochrane Headline outcomes only
  RR 5.44
  1 study · 3022 participants
  Low

Effect of LF‐LAM vs no LF‐LAM on mortality and tuberculosis treatment initiation

Effect of LF‐LAM showed no clear difference in mortality at 6 months compared with no LF‐LAM on mortality and tuberculosis treatment initiation (low certainty).

• Impact of diagnostic strategies for tuberculosis using lateral flow urine lipoarabinomannan assay in people living… 2021 · Cochrane Headline outcomes only
  RR 0.89 [0.71, 1.11]
  1 study · 2972 participants
  Low

Oral 5‐ASA vs placebo

Oral 5‐ASA leads to lower failure to induce complete global or clinical remission compared with placebo (high certainty).

• Oral 5‐aminosalicylic acid for induction of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
  RR 0.86 [0.82, 0.89]
  11 studies · 2387 participants
  High